Monday, August 24, 2020

Very Brief Blog: THRIVE raises $257M, Quest Sends Me Email to Enroll in LBX Occult Cancer Trial

This summer, the Johns Hopkins spinout THRIVE raised an extra $257M for clinical trials of liquid biopsy cfDNA tests to detect occult cancers (here).

Today's emails brought me an invitation from QUEST to enroll in the THRIVE-ASCEND LBx trial, a large study to screen healthy people for possible occult cancers.   Screen shot below.